Synbody Biotechnology (SBI) is a start-up biotechnology company based on a powerful synthetic antibody, or "Synbody,"  technology recently discovered at Arizona State University.  Synbodies revolutionize the field of high affinity, high specificity therapeutic agents by creating antibody-like function from small purely synthetic peptides.  It is SBI's mission to leverage the Synbody technology to create a pipeline of superior human therapeutics across multiple therapeutic areas.  SBI seeks to realize the opportunity for synbodies as human therapeutics through a combined strategy comprising corporate partnerships, out-licensing agreements and in-house development.